Stock Analysis

High Growth Tech Stocks In Hong Kong Including Tencent Holdings

SEHK:700
Source: Shutterstock

In recent times, the Hong Kong market has experienced fluctuations with the Hang Seng Index seeing a decline of 2.11%, reflecting broader economic challenges and investor sentiment shifts. In this environment, high-growth tech stocks such as Tencent Holdings are drawing attention for their potential to navigate these dynamics effectively, offering investors opportunities in innovation-driven sectors.

Top 10 High Growth Tech Companies In Hong Kong

NameRevenue GrowthEarnings GrowthGrowth Rating
Wasion Holdings22.37%25.47%★★★★★☆
MedSci Healthcare Holdings48.74%48.78%★★★★★☆
Inspur Digital Enterprise Technology23.30%38.78%★★★★★☆
RemeGen26.23%52.03%★★★★★☆
Cowell e Holdings31.68%35.44%★★★★★★
Innovent Biologics22.11%59.31%★★★★★☆
Akeso33.50%53.12%★★★★★★
Biocytogen Pharmaceuticals (Beijing)21.53%109.17%★★★★★☆
Beijing Airdoc Technology37.47%93.35%★★★★★☆
Sichuan Kelun-Biotech Biopharmaceutical24.70%8.53%★★★★★☆

Click here to see the full list of 43 stocks from our SEHK High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Tencent Holdings (SEHK:700)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Tencent Holdings Limited is an investment holding company that provides value-added services, online advertising, fintech, and business services in China and globally, with a market capitalization of approximately HK$3.87 trillion.

Operations: Tencent generates significant revenue from its Value-Added Services (VAS), which account for CN¥302.28 billion, and Fintech and Business Services, contributing CN¥209.17 billion. Online advertising also plays a crucial role with revenues of CN¥111.89 billion.

Tencent Holdings, amidst a challenging market, is navigating through strategic mergers and acquisitions, notably considering teaming up for a potential buyout of Ubisoft. This move could stabilize the latter's declining value and enhance Tencent's influence in the gaming sector. Financially, Tencent has demonstrated robust growth with revenue rising to CNY 320.62 billion in the first half of 2024 from CNY 299.19 billion in the prior year, marking an increase that outpaces many local peers. Moreover, its earnings surged by over 72% to CNY 89.52 billion, reflecting strong operational efficiency and strategic investments that could bolster future growth prospects in both domestic and international markets.

SEHK:700 Earnings and Revenue Growth as at Oct 2024
SEHK:700 Earnings and Revenue Growth as at Oct 2024

Lenovo Group (SEHK:992)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lenovo Group Limited is an investment holding company that develops, manufactures, and markets technology products and services, with a market cap of approximately HK$139.18 billion.

Operations: The company generates revenue primarily through its Intelligent Devices Group (IDG), contributing $45.76 billion, followed by the Infrastructure Solutions Group (ISG) at $10.17 billion, and the Solutions and Services Group (SSG) at $7.64 billion.

Lenovo Group is making significant strides in integrating AI into diverse tech solutions, evidenced by its recent collaboration with Red Hat to optimize AI computing on Lenovo ThinkSystem servers. This partnership underscores Lenovo's commitment to enhancing AI infrastructure, which is critical as industries increasingly rely on high-performance computing for AI applications. The company's R&D expenses have been robust, maintaining a consistent reinvestment rate of 7.9% of its revenue back into research and development, reflecting a deliberate strategy to fuel innovation and stay competitive in the high-tech market. Furthermore, Lenovo's earnings are projected to grow by 18.7% annually, highlighting its potential resilience and adaptability in a rapidly evolving tech landscape.

SEHK:992 Earnings and Revenue Growth as at Oct 2024
SEHK:992 Earnings and Revenue Growth as at Oct 2024

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of antibody drugs with a market capitalization of HK$59.24 billion.

Operations: The company generates revenue primarily from the research, development, production, and sale of biopharmaceutical products, amounting to CN¥1.87 billion.

Akeso is making waves in the high-growth tech sector in Hong Kong, particularly with its recent groundbreaking results from the COMPASSION-16 study for cervical cancer treatment. The company's commitment to innovation is evident as it reinvests a significant portion of its revenue into R&D, maintaining an expenditure rate of 33.5% annually. This strategic focus has facilitated a projected earnings growth rate of 53.1%, positioning Akeso uniquely among peers in biotech advancements. Moreover, the successful HKD 1.94 billion equity offering underscores market confidence and bolsters its financial capacity to sustain aggressive research pursuits, promising a robust pipeline and potential market expansions.

SEHK:9926 Revenue and Expenses Breakdown as at Oct 2024
SEHK:9926 Revenue and Expenses Breakdown as at Oct 2024

Summing It All Up

  • Dive into all 43 of the SEHK High Growth Tech and AI Stocks we have identified here.
  • Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
  • Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Tencent Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com